Reckitt Benckiser Group (LON:RB) had its target price lifted by research analysts at JPMorgan Chase & Co. from to in a report released on Tuesday. The brokerage presently has an “overweight” rating on the stock.
A number of other equities research analysts have also commented on the stock. Barclays reaffirmed an “equal weight” rating and issued a GBX 6,450 ($83.20) price objective on shares of Reckitt Benckiser Group in a research note on Tuesday. Citigroup reaffirmed a “buy” rating and issued a GBX 7,650 ($98.68) price objective (up from GBX 7,200 ($92.88)) on shares of Reckitt Benckiser Group in a research note on Thursday, August 30th. Credit Suisse Group reaffirmed an “underperform” rating on shares of Reckitt Benckiser Group in a research note on Thursday, August 23rd. Royal Bank of Canada upped their price objective on shares of Reckitt Benckiser Group from GBX 4,500 ($58.05) to GBX 5,100 ($65.79) and gave the company an “underperform” rating in a research note on Monday, August 6th. Finally, Liberum Capital upped their price objective on shares of Reckitt Benckiser Group from GBX 7,400 ($95.46) to GBX 7,600 ($98.04) and gave the company a “buy” rating in a research note on Thursday, August 2nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company’s stock. Reckitt Benckiser Group presently has an average rating of “Hold” and an average price target of GBX 7,080.95 ($91.34).
Shares of LON:RB traded down GBX 12 ($0.15) during trading on Tuesday, reaching GBX 6,456 ($83.28). The stock had a trading volume of 813,982 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 52 week low of GBX 5,562 ($71.75) and a 52 week high of GBX 8,110.43 ($104.62).
Reckitt Benckiser Group Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Read More: Understanding Analyst Recommendations
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.